Cite
MLA Citation
Javier Cortés et al.. “Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.” Lancet oncology, vol. 16, no. 16, 2015, pp. 1700–1710. http://access.bl.uk/ark:/81055/vdc_100029474807.0x000020